Infection News

Healio Gastroenterology and Liver Disease presents the following reports on the most recent research and news on the gut microbiome.

Patients with inflammatory bowel disease who received long-duration vancomycin as treatment for Clostridioides difficile infection had lower recurrence rates compared with patients who receive shorter durations of the drug, according to study results.

The CDC announced a multistate outbreak of Escherichia coli 0157:H7 infections linked to romaine lettuce harvested from the growing region in Salinas, California.

NEW YORK — In this video, Joseph A. Bocchini Jr., MD, professor and chairman of the department of pediatrics at Louisiana State University Health Sciences Center, discusses common travel-related infections.

This year’s The Liver Meeting provided many exciting updates for viral hepatitis care ranging from steps toward eliminating hepatitis C to improving hepatitis B treatment options through data on hepatitis D.

Trio Health presented results from four studies at The Liver Meeting 2019 that showed novel outcomes in patients treated for hepatitis B with Vemlidy or hepatitis C with Vosevi.

The FDA approved changes to the product labels for direct-acting antivirals Harvoni, Epclusa, and Vosevi to include new efficacy and safety data for adults with hepatitis C and severe renal impairment, including those who require dialysis.

The first duodenoscope with a sterilized and disposable elevator component that reduces the number of parts in need of cleaning and disinfection between uses has received FDA clearance for marketing in the United States, according to an FDA press release.

BOSTON — The Hepatitis C Leaders in Primary Care program, or HELP-C, engaged primary care physicians to successfully screen and treat veterans with hepatitis C through comanagement with a specialist liver team, according to a study presented at The Liver Meeting 2019.

BOSTON — Triple combination therapy with lonafarnib, ritonavir, and Lambda for chronic hepatitis D appeared safe and tolerable for up to 6 months in most patients and led to high rates of RNA decline, according to data presented at The Liver Meeting 2019.